Nike NKE Q1 2026 Earnings EPS Beats Estimates by 2289 Stock Edges Higher HTGC Q1 2026 Earnings EPS Misses Estimates by a Narrow Margin Dogwood Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Amid Continued Preclinical Development Recursion Pharmaceuticals RXRX Q1 2026 Earnings Narrower Loss Surprises Market but Stock Dips on PreRevenue Status HOVR Q1 2026 Earnings EPS Misses Estimates PreRevenue Development Continues VVV Q1 2026 Earnings Strong EPS Beat Highlights Operational Efficiency